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Summ a r y
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province 
in the Democratic Republic of Congo, EVD was diagnosed in a patient who had 
received the recombinant vesicular stomatitis virus–based vaccine expressing a 
ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus 
(EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. 
However, 6 months later, he presented again with severe EVD-like illness and 
EBOV viremia, and he died. We initiated epidemiologic and genomic investigations 
that showed that the patient had had a relapse of acute EVD that led to a transmis-
sion chain resulting in 91 cases across six health zones over 4 months. (Funded 
by the Bill and Melinda Gates Foundation and others.)
Human-to-human transmission of Ebola virus (EBOV) typically occurs through direct contact with infectious blood or bodily fluids (e.g., semen or breast milk).1 EBOV persistence has been well documented in 
survivors of Ebola virus disease (EVD). Although secondary transmission through 
contact with infectious bodily fluids is relatively rare, it has been linked to flare-up 
events.2 In two survivors of EVD, meningoencephalitis and uveitis syndromes have 
been associated with infectious EBOV in cerebrospinal fluid and aqueous humor, 
respectively; neither case led to further transmission.3,4 Here, we report the relapse 
of acute EVD in a patient who was infected with the EBOV Ituri variant during the 
2018–2020 North Kivu EVD outbreak in the Democratic Republic of Congo (DRC).5 
The relapse, which occurred 149 days after the patient was discharged from an 
Ebola treatment unit, sparked a transmission chain of 91 cases.
C a se R eport
Patient History and Epidemiologic Findings
A 25-year-old man who worked as a motorcycle taxi driver presented to the Ebola 
treatment unit (ETU) in Mangina, DRC, on June 15, 2019, with a 2-day history 
of fever, nausea, vomiting, asthenia, anorexia, myalgia, and chest pain. Accord-
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ing to the patient’s medical record, he had re-
ceived the recombinant vesicular stomatitis virus–
based vaccine expressing a ZEBOV glycoprotein 
(rVSV-ZEBOV)6 (Merck, lot number WL00064825) 
6 months previously (on December 6, 2018) be-
cause he was a contact of a person with con-
firmed EVD. Despite his previous vaccination, 
we detected EBOV RNA in the patient’s serum 
with the use of the GeneXpert platform (Xpert 
Ebola Assay, Cepheid) (Table 1), and EVD was 
diagnosed.
We initiated treatment with the experimental 
mAb114 monoclonal antibody7 on June 16, 2019, 
under the Monitored Emergency Use of Unregis-
tered and Investigational Interventions protocol.8 
In addition, we provided standard supportive care 
that included an antibiotic agent (intravenous 
ceftriaxone), an antimalarial agent (artesunate–
amodiaquine), a proton-pump inhibitor (omepra-
zole), and magnesium supplementation. The pa-
tient was discharged from the ETU on June 29 
after two consecutive negative results on a poly-
merase-chain-reaction assay (Fig. 1 and Table 1). 
On August 27, a semen sample was collected as 
part of the national program to monitor EVD 
survivors, and the test result was negative for 
EBOV RNA (Table 1). The patient did not undergo 
follow-up for additional semen testing.
On November 25, 2019, a total of 149 days 
after discharge from the ETU, headache, asthenia, 
myalgia, polyarthralgia, and anorexia developed 
in the patient. He was seen at a local health 
center, where he received unspecified treatment. 
On November 26, he had nausea, diarrhea, me-
lena, jaundice, conjunctival injection, epistaxis, 
and abdominal, chest, and spinal pain. The patient 
consulted a traditional practitioner, was hospital-
ized for 2 days, and received unspecified treat-
ment. After the symptoms increased in severity, 
community members alerted the EVD response 
team, and 8 days after the onset of illness (on 
December 3), the patient was transferred to the 
ETU in Mangina. He had transient loss of con-
sciousness soon after arrival. Initial clinical ex-
amination revealed a bedridden patient with pale 
palpebral conjunctiva, icteric bulbar conjunctiva, 
a soft abdomen with epigastric tenderness, swell-
ing of the left arm, and tender ecchymosis and 
bleeding at a venipuncture site. The vital signs 
on arrival included a heart rate of 91 beats per 
minute, respiratory rate of 26 breaths per min-
ute, and blood pressure of 100/60 mm Hg; the 
oxygen saturation as measured by pulse oxime-
try was 99%. The results of rapid diagnostic 
tests to detect human immunodeficiency virus 
(HIV) infection (Determine, Abbott) and malaria 
were negative. A serum sample obtained on De-
cember 3 tested positive for EBOV RNA (Table 1), 
Table 1. Diagnostic Test Results in Samples Obtained during the First and Second Episodes of EVD in the Patient in 2019.*














Sample d1: MAN4194 June 15 Serum 32.5 29.9 Negative Yes
MAN4337 June 18 Serum Negative 41.7 — —
MAN4434 June 20 Serum 41.3 39.2 — —
MAN4524 June 22 Serum Negative 38.5 — —
MAN4694 June 25 Serum Negative 38.0 — —
MAN4796 June 27 Serum Negative Negative — —
Sample d14: MAN4907 June 29 Serum Negative Negative 1:77,579 —
Identifier unknown Aug. 27 Semen Negative Negative — —
Sample d171: MAN12309 Dec. 3 Serum 33.3 30.1 1:164,609 Yes
Sample d173: MAN12369 Dec. 5 Oral swab 28.7 24.8 — Yes
*  The glycoprotein and nucleoprotein targets of Ebola virus RNA were detected with the use of GeneXpert diagnostic quantitative reverse-
transcriptase–polymerase-chain-reaction assays (Xpert Ebola Assay, Cepheid) and are expressed as cycle-threshold (Ct) values. Glycoprotein 
binding titers were assessed with the use of an enzyme-linked immunosorbent assay (Alpha Diagnostic International) with a readout for the 
anti-Ebola glycoprotein IgG EC50 (the concentration at which there is a 50% decrease in antigen binding). EVD denotes Ebola virus disease.
†  Sample identifiers were assigned only to the samples described in this article.
‡  Samples from which full viral genomes were determined are indicated.
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and he received a diagnosis of EVD for the sec-
ond time in 6 months.
The patient received antibiotics (ceftriaxone, 
metronidazole, and amoxicillin–clavulanate), an 
antimalarial agent (artesunate–amodiaquine), a 
proton-pump inhibitor (omeprazole), an anti-
emetic agent (ondasetron), and rehydration fluid. 
On December 4, 2019, his condition deteriorated, 
with loss of consciousness, gingivorrhagia, ane-
mia, and dyspnea associated with painful hepa-
tomegaly on palpation. Clinical laboratory tests 
revealed acute kidney injury, liver injury (elevated 
hepatic aminotransferase levels and hyperbiliru-
binemia), hyponatremia, severe hypoalbumin-
emia, and a markedly elevated C-reactive protein 
level; all these findings were consistent with 
multiorgan failure or dysfunction (Table S1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org).
The patient received oxygen and a blood trans-
fusion. Despite this treatment, acute respiratory 
distress and coma developed, and the patient died. 
A postmortem oral swab obtained on December 
5, 2019, was positive for EBOV RNA (Table 1).
An epidemiologic investigation was initiated. 
Contact tracers connected the patient to 29 per-
sons with EVD who had had exposure to the 
patient while he was symptomatic in the com-
munity or while he had visited local health clin-
ics for treatment. An additional 62 cases resulted 
from onward transmission from these initial 
contacts. Overall, the cases spanned six health 
zones over 4 months.
 Molecular and Serologic Investigations
We initiated a genomic investigation to support 
the epidemiologic findings and differentiate be-
tween relapse and reinfection in this patient (i.e., 
to differentiate between recurrence of the initial 
disease that had occurred in June 2019 and re-
infection through an active transmission chain in 
November 2019). We sequenced serum samples 
obtained during the first infection on June 15 
(sample d1) and during the second infection on 
December 3 (sample d171), as well as a postmor-
tem oral swab (sample d173). We also sequenced 
diagnostic samples obtained from 72 epidemio-
logically linked cases (Table S2). Our compari-
son of these samples with previously sequenced 
samples from the North Kivu outbreak revealed 
that all our patient’s samples (samples d1, d171, 
and d173) and those from the 72 epidemiologi-
Figure 1. Timeline of the First and Second Episodes of EVD in the Patient, from December 2018 through December 2019.
ETU denotes Ebola treatment unit, EVD Ebola virus disease, MEURI Monitored Emergency Use of Unregistered and 
Investigational Interventions, RT-PCR reverse transcriptase–polymerase chain reaction, and rVSV-ZEBOV recombi-
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cally linked cases shared a unique mutation in 
the glycoprotein (G6800A/E258K) that separated 
these sequences from other sequences in the out-
break (Fig. S1A). The samples obtained during 
the second infection (samples d171 and d173) 
and those from the 72 epidemiologically linked 
cases shared two unique mutations (T5578C non-
coding and glycoprotein A6867G/E280G) that 
genetically linked the cluster and indicated that 
the sample d1 sequence was ancestral to the 
relapse cluster (Fig. 2A and Fig. S1B).
We performed a Bayesian phylodynamic analy-
sis to reconstruct a time-resolved phylogeny with 
the use of all the North Kivu outbreak EBOV 
genomes with at least 95% coverage (Fig. 2B). 
We determined the overall rate of evolution for 
the EBOV Ituri variant in the ongoing North Kivu 
outbreak to be 0.8 × 10−3 substitutions per genomic 
site per year (95% highest posterior density in-
terval, 0.7 × 10−3 to 0.9 × 10−3), which is consistent 
with the rates observed during the 2013–2016 
West African epidemic.9 The branch leading to 
sample d171 had a reduced rate of 0.2 × 10−3 sub-
stitutions per genomic site per year (95% highest 
posterior density interval, 0.1 × 10−3 to 0.3 × 10−3) 
(Fig. 2B and Fig. S2). This slowing of the molecu-
lar clock was consistent with persistent EBOV 
infection.10-13 The median estimated time to the 
most recent common ancestor (TMRCA) of all 
relapse clade genomes was November 7, 2019 
(95% highest posterior density interval, October 
15 to November 24), which is consistent with 
recurrence of symptoms in the patient on Novem-
ber 25 and with onward transmission shortly 
after. Taken together, our phylogenetic and epi-
demiologic data show that the patient’s second 
EVD episode was the result of EVD relapse from 
his initial EBOV infection and was not due to 
reinfection.
To investigate the potential failure of vaccine 
protection at the patient’s initial clinical presen-
tation and relapse, we assayed the patient’s sam-
ples for anti-EBOV glycoprotein IgG antibody 
titers. We were unable to detect anti-EBOV glyco-
protein IgG in sample d1, but we detected high 
titers in a sample obtained 14 days later (in sam-
ple d14) and in a sample obtained 8 days after 
the onset of relapse-associated illness (sample 
d171) (Table 1 and Fig. S3). On the basis of the 
half-life of mAb114 (approximately 24 days),14 
the sample d14 results partially indicated detec-
tion of residual mAb114. However, more than 
99% of mAb114 would have been cleared when 
sample d171 was obtained. The higher titer in 
sample d171 probably resulted from recall anti-
body responses to the recurring infection, pri-
mary antibody responses to the recurring infec-
tion, or both, in the patient. Thus, the relapse is 
not explained by a failed antibody response, and 
some other immune deficit (acquired or primary 
immune deficiency) may have played a role. Given 
the patient’s negative HIV test, we investigated 
the possibility of primary immune deficiencies to 
explain the patient’s course of disease and vac-
cine failure. We sequenced the patient’s exome, 
but no variants that were known to or likely to 
cause primary immune deficiencies were detected 
(Table S3 and Fig. S4).
Although the location of the mutations 
(G6800A/E258K and A6867G/E280G) in the viral 
envelope glycoprotein are distant from the 
mAb114 binding site,7 it is reasonable to con-
sider whether these mutations resulted from viral 
escape from mAb114 treatment. To test for this 
possibility, we evaluated the ability of mAb114 to 
neutralize viruses bearing the mutant glycopro-
teins (Table 1 and Fig. S5). The data showed 
nearly identical neutralization by mAb114 of both 
wild-type Ituri and the glycoprotein variant de-
tected in our patient’s viral genomes; thus, in 
vitro, the glycoprotein variation was independent 
of mAb114 selective pressures.
Discussion
We describe a case of acute EVD relapse that has 
led to human-to-human transmission. We were 
able to sequence EBOV genomes in samples ob-
tained during the patient’s first EVD episode 
(sample d1) and second EVD episode (sample 
d171), and we found that they differed by only 
two mutations. These findings indicate a relapse 
of the initial EBOV infection. Our time-aware 
phylodynamic analysis showed that between 
samples d1 and d171, the virus evolved at a rate 
that was one quarter of that in the overall out-
break; this finding indicates relapse from a per-
sistent EBOV infection. The median TMRCA for 
the relapse clade of November 7, 2019, is an es-
timate of the earliest time point when the virus 
probably exited persistence and resumed a normal 
rate of replication. If we assume a presymptom-
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atic incubation period of 2 to 21 days, this date 
is consistent with the recurrence of EVD symp-
toms on November 25 reported by the patient.
Although the underlying mechanism of re-
lapse associated with EBOV persistence in con-
valescent patients remains unclear, three patients 
with documented cases of relapse (including the 
patient reported here) all received antibody-
based therapy as part of the treatment for the 
initial infection. The Pamoja Tulinde Maisha 
(PALM [“Together Save Lives” in the Kiswahili 
language]) randomized, controlled trial showed 
the benefits of monocolonal antibody–based 
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immunotherapy could, in rare instances, be asso-
ciated with viral relapse, as has been historically 
documented in patients with Argentine hemor-
rhagic fever treated with convalescent plasma.16 
Two previous patients with EVD relapse were 
repatriated persons who had severe EVD and 
received aggressive supportive care along with 
convalescent plasma and experimental therapeu-
tic agents.3,17,18 Both patients recovered, and dur-
ing convalescence, organ-specific inflammatory 
syndromes (uveitis and meningoencephalitis) de-
veloped that warranted additional treatment.3,4
The major and very consequential distinction 
between our patient and previous patients with 
relapse is the extent of onward transmission. 
Our patient was symptomatic in the community 
for 8 days and visited two health care centers. 
Precautions were not taken to prevent the spread 
of infection, and there were 29 directly linked 
cases of EVD. This case report provides an un-
fortunate proof-of-principle that survivors of EVD 
with relapse syndromes, like patients with acute 
EVD, can transmit EBOV.
To investigate why the patient was not pro-
tected from infection after his vaccination in 
December 2018, we tested a serum sample ob-
tained during his initial EVD episode in June 
2019 for anti–EBOV glycoprotein IgG titers, but 
we detected none (Table 1). Given that we found 
no signs of immune deficiencies, this probably 
was an incidence of temporal or complete vac-
cine failure. This finding is in line with those of 
other studies showing that up to 10% of patients 
with EVD had been fully vaccinated for at least 
10 days before admission to the ETU.15 In addi-
tion, serologic data from the Partnership for 
Research on Ebola Virus in Liberia (PREVAIL) 
trials involving more than 700 participants who 
had received rVSV-ZEBOV showed that in approxi-
mately 20% of vaccinated persons, positive Ebola 
IgG binding titers did not develop 1 month after 
vaccination.19,20 Combined, these findings arouse 
concerns about the true effectiveness of rVSV-
ZEBOV, which has been estimated to be 100% 
in the Guinean “Ebola ça suffit!” trial21 and 
97.5% in the preliminary report by the World 
Health Organization on the use of this vaccine 
in the DRC.22
An alternative hypothesis for the patient’s lack 
of protection during relapse, despite his anam-
nestic response, is potential viral escape during 
persistence. The E280G glycoprotein mutation 
that developed during EBOV persistence may have 
allowed a replication advantage or immune es-
cape, but our data show that the mutated glyco-
proteins retained sensitivity to the treatment anti-
body mAb114. Alternatively, the mutation may 
simply be coincidental, and viral persistence 
may have arisen with infection of an immune-
privileged compartment. The other noted muta-
tion in this patient was in a noncoding region, 
and little is known about the effect of an intra-
genic region on gene expression in EBOV. Fur-
thermore, our patient did not have overt evidence 
of chronic diseases associated with immunosup-
pression, and our whole-exome sequencing analy-
sis did not reveal genomic variants that are 
known to or likely to cause primary immune 
Figure 2 (facing page). Epidemiologic and Phylogenetic 
Analysis of the Case of Relapse and Linked Cases.
We initiated investigations that showed that the patient 
had had a relapse of acute Ebola virus disease (EVD) 
that led to a transmission chain resulting in 91 cases 
across six health zones in the Democratic Republic of 
Congo (DRC). Panel A shows a haplotype network of 
the case of EVD relapse and 72 epidemiologically linked 
cases across five of the six health zones for which we 
had obtained sequence data from samples. The size of 
the circles is proportional to the number of cases, and 
the hatch marks indicate the number of substitutions 
along each edge. Panel B shows a maximum clade 
credibility tree with a two-rate clock model in which 
branches indicating persistent infection were allowed 
to have a rate of evolution that was different than that 
in the rest of the tree. The tree was estimated with the 
use of 297 sequenced isolates with greater than 95% 
coverage from the current North Kivu EVD outbreak in 
the DRC; these isolates were differentiated according to 
health zone. The branch colors indicate the evolutionary 
rate in substitutions per genomic site per year. Black 
circles indicate internal nodes of the tree with a posterior 
probability of greater than 50%. An enlarged view of the 
time tree shows the first episode (sample d1) and sec-
ond episode (sample d171) of EVD in the patient with 
relapse, as well as 61 viral genomes sampled from epi-
demiologically linked cases. The 95% highest posterior 
density of the estimated time to the most recent com-
mon ancestor (TMRCA) for the relapse clade is shown. 
The median TMRCA was estimated to be November 7, 
2019 (95% highest posterior density interval, October 
15 to November 24). The evolutionary rate between 
samples d1 and d171 is four times lower than that in 
the overall outbreak. Data are from Nextstrain (https://
nextstrain . org/ community/ inrb - drc/ ebola - nord - kivu) 
and were released on the National Center for Biotech-
nology Information GenBank database.
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deficiencies, although primary immunodeficien-
cy cannot be fully ruled out.
During the North Kivu outbreak in the DRC, 
the provision of effective therapeutic agents for 
EVD and supportive care have helped more than 
1000 patients to leave ETUs as survivors (who are 
aptly called “vainqueurs” or victors, in French).15 
Despite the positive effect these countermeasures 
may have had on individual lives, the overall 
case fatality rate of approximately 66% is similar 
to those observed during previous outbreaks.23 
This high case fatality rate can be partially at-
tributed to the fact that the outbreak occurred in 
a conflict zone, with frequent disruptions to all 
aspects of the outbreak response.24,25 This case 
report shows the need for continued monitoring 
of vaccine and therapeutic interventions and the 
power of having locally available genomic capa-
bilities to support the outbreak response. Relapse 
of EVD appears to be a rare event; however, re-
lapse, like sexual transmission, should be recog-
nized as a mechanism for onward transmission 
from persons with persistent infections. More 
data are needed to understand the mechanism 
and risk factors of EVD relapse in order to pre-
vent future transmission events and protect pa-
tients as well as their families and communities.
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